Home » Stocks » MGNX

MacroGenics, Inc. (MGNX)

Stock Price: $22.84 USD 0.43 (1.92%)
Updated November 25, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.28B
Revenue (ttm) 77.38M
Net Income (ttm) -158.05M
Shares Out 56.20M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $22.84
Previous Close $22.41
Change ($) 0.43
Change (%) 1.92%
Day's Open 22.47
Day's Range 22.30 - 23.36
Day's Volume 374,726
52-Week Range 4.04 - 32.18

More Stats

Market Cap 1.28B
Enterprise Value 1.03B
Earnings Date (est) Mar 2, 2021
Ex-Dividend Date n/a
Shares Outstanding 56.20M
Float 54.55M
EPS (basic) -3.13
EPS (diluted) -3.12
FCF / Share -2.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.14M
Short Ratio 9.69
Short % of Float 7.59%
Beta 2.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 16.59
PB Ratio 4.19
Revenue 77.38M
Operating Income -167.55M
Net Income -158.05M
Free Cash Flow -148.00M
Net Cash 252.20M
Net Cash / Share 4.49
Gross Margin -169.44%
Operating Margin -216.51%
Profit Margin -204.20%
FCF Margin -191.26%
ROA -28.85%
ROE -57.81%
ROIC -105.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 2

Analyst Consensus: Buy

Price Target

$28.33*
(24.04% upside)
Low
8.00
Current: $22.84
High
38.00
Target: 28.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue64.1960.1215891.8810147.8058.0463.8357.21
Revenue Growth6.76%-61.89%71.68%-8.9%111%-17.64%-9.07%11.57%-
Gross Profit64.1960.1215891.8810147.8058.0463.8357.21
Operating Income-177-171-22.14-60.04-20.18-38.320.378.215.25
Net Income-152-171-19.63-58.53-20.14-38.31-0.268.366.72
Shares Outstanding48.0840.9336.1034.6931.8027.386.851.081.03
Earnings Per Share-3.16-4.19-0.54-1.69-0.63-1.40-0.04--
Operating Cash Flow-134-15314.41-43.68-13.66-32.76-14.17-6.586.76
Capital Expenditures-4.29-24.95-29.40-11.38-9.20-3.57-2.96-0.94-0.50
Free Cash Flow-139-178-15.00-55.06-22.86-36.33-17.13-7.526.26
Cash & Equivalents21623330527733915811748.1555.80
Total Debt30.57--------
Net Cash / Debt18523330527733915811748.1555.80
Assets31333237431135917412653.7562.68
Liabilities81.8789.2574.6542.5145.9352.6046.8761.9880.16
Book Value23124329926931312178.91-8.240.27
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MacroGenics, Inc.
Country United States
Employees 384
CEO Scott E. Koenig

Stock Information

Ticker Symbol MGNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MGNX
IPO Date October 10, 2013

Description

MacroGenics, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.